Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.
Thomas Willemsen
Advertisement
Articles by Thomas Willemsen
Advertisement
Latest Updated Articles
Targeting Hematological Malignancies With Autologous and Allogeneic Cell TherapiesPublished: November 22nd 2022 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Steven W. Pipe, MD, on the Implications of the Final Data From Hemgenix’s HOPE-B Trial
2
What the Field of Cell and Gene Therapy Needs Most in the Current Moment
3
Rabi Hanna, MD, on Practical Considerations for Integrating Gene Therapy
4
End-of-Study Results From Hemgenix’s HOPE-B Trial
5
